TCAF1 Variant 2 as A Drug Target for Alzheimer's Disease (G9747)

Target Name: TCAF1

NCBI ID: G9747

TCAF1

TCAF1 Variant 2 as A Drug Target for Alzheimer's Disease

TCAF1 (TCAF1 variant 2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the TCAF family, which consists of six transmembrane proteins that are involved in the regulation of cell adhesion, migration, and signaling pathways.

The TCAF1 protein is unique because it has a unique variant, known as TCAF1 variant 2, which is associated with decreased function and increased sensitivity to drugs in patients with Alzheimer's disease. This variant has been identified as a drug target (or biomarker) for the development of new treatments for Alzheimer's disease.

TCAF1 is involved in several signaling pathways that are important for the development and progression of Alzheimer's disease. One of the most well-studied signaling pathways involves the TCAF1-Fz complex, which is involved in the regulation of the production and degradation of neurotransmitters, such as beta-amyloid peptides.

Research has shown that TCAF1 variant 2 is associated with decreased levels of beta-amyloid peptides in the brain, which are thought to contribute to the development and progression of Alzheimer's disease. This suggests that TCAF1 variant 2 may be an attractive drug target for the development of new treatments for Alzheimer's disease.

In addition to its role in the regulation of beta-amyloid peptides, TCAF1 is also involved in the regulation of several other signaling pathways that are important for the development and progression of Alzheimer's disease. For example, TCAF1 is involved in the regulation of the production and degradation of neurotransmitters, such as dopamine and synaptophysin, which are involved in the regulation of movement and cognitive function.

TCAF1 variant 2 has also been shown to be involved in the regulation of the production and degradation of other neurotransmitters, such as GABA and vasopressin. These neurotransmitters are involved in the regulation of mood, anxiety, and other physiological processes that are important for the development and progression of Alzheimer's disease.

In conclusion, TCAF1 variant 2 is a protein that is involved in several signaling pathways that are important for the development and progression of Alzheimer's disease. The decreased function of TCAF1 variant 2 in the regulation of beta-amyloid peptides and other neurotransmitters suggests that it may be an attractive drug target for the development of new treatments for Alzheimer's disease. Further research is needed to determine the exact role of TCAF1 variant 2 in the development and progression of Alzheimer's disease, and to identify potential new treatments for this debilitating and progressive disease.

Protein Name: TRPM8 Channel Associated Factor 1

Functions: Positively regulates the plasma membrane cation channel TRPM8 activity. Involved in the recruitment of TRPM8 to the cell surface. Promotes prostate cancer cell migration inhibition in a TRPM8-dependent manner

The "TCAF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCAF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets